Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Global Blood Therapeutics
South San Francisco, California, United Statesgbt.com ↗
- Ownership
- Private
- Employees
- ~444
- Development stage
- Other
01
Overview
Global Blood Therapeutics developed Oxbryta® (voxelotor), the first FDA-approved oral therapy that directly inhibits hemoglobin polymerization—the root cause of red blood cell sickling in SCD. Approved by the FDA in November 2019 for patients aged ≥12 years and subsequently expanded to younger pediatric populations. The company also advanced a robust pipeline including GBT601 and inclacumab—both with orphan drug designations—targeting different aspects of SCD pathophysiology. In October 2022, Pfizer acquired GBT for $5.4 billion to expand its rare hematology portfolio[3][7][8].
- Therapeutic areas
- HematologyPulmonologyRare Diseases
- Modalities
- small molecules (notably Oxbryta/voxelotor and pipeline assets)monoclonal antibodies (inclacumab)
- Industry
- Biotech
02
Partnerships
Sanofi – acquisition/licensing of two additional sickle cell compounds[9]
Beyond the preview
Go deeper on Global Blood Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Global Blood Therapeutics.